Many studies have been addressed to determine the HER2-positive rate, mainly in breast and gastric carcinomas, utilizing a well codified scoring system [10,11], and HER2 status assessment is currently being used in such cancers to determine patient eligibility for treatment with trastuzumab [8,9,12,13]. This evidence concerns the gene ERBB2 and cancer.